Délphine Legoupil

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas

E. Maubec, Marouane Boubaya, Peter Petrow et al. · Journal of Clinical Oncology · 2020 · 174 citations

Medicine, Oncology, Pharmacology +16

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network

Julie Delyon, Sylvie Chevret, Thomas Jouary et al. · Journal of Investigative Dermatology · 2017 · 58 citations · Full text

Medicine, Oncology, Pharmacology +17

Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort

M. Kandel, Clara Allayous, Stéphane Dalle et al. · European Journal of Cancer · 2018 · 38 citations

Pharmacy, Oncology, Pharmacoeconomics +14

Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort

Pauline Tétu, Clara Allayous, Bastien Oriano et al. · European Journal of Cancer · 2019 · 35 citations

Medicine, Oncology, Radiation Oncology +14

Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study

Léo Plaçais, Stéphane Dalle, O. Dereure et al. · Annals of the Rheumatic Diseases · 2022 · 34 citations · Full text

Life Sciences, Immunology, Oncology +14